Animal models of respiratory syncytial virus infection

Vaccine

Volumn 35, Issue 3, 2017, Pages 469-480

  Taylor, Geraldine ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Animal models; Respiratory syncytial virus

Indexed keywords

MONOCLONAL ANTIBODY; VACCINE;

ANIMAL MODEL; ARTICLE; BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION; CALF (BOVINE); CHIMPANZEE; CHLOROCEBUS AETHIOPS; COTTON RAT; EXPERIMENTAL INFECTION; FERRET; HUMAN; MACACA; MOUSE; NATURAL HOST; NONHUMAN; PNEUMOVIRUS; PRIMATE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RODENT; SHEEP; VIRUS PNEUMONIA; VIRUS REPLICATION; ANIMAL; DISEASE MODEL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PATHOLOGY; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 85006377667     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.054     Document Type: Article

References (160)

1. [1] Nair, H., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555.
2. [2] Hall, C.B., et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:4 (1991), 693–698.
3. [3] Falsey, A.R., Walsh, E.E., Viral pneumonia in older adults. Clin Infect Dis 42:4 (2006), 518–524.
4. [4] Hall, C.B., Simoes, E.A., Anderson, L.J., Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 372 (2013), 39–57.
5. [5] Chemaly, R.F., Shah, D.P., Boeckh, M.J., Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 59:Suppl. 5 (2014), S344–S351.
6. [6] Falsey, A.R., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:17 (2005), 1749–1759.
7. [7] Fleming, D.M., Elliot, A.J., Respiratory syncytial virus: a sleeping giant?. Eur Respir J 30:6 (2007), 1029–1031.
8. [8] Cardenas, S., Auais, A., Piedimonte, G., Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3:5 (2005), 719–726.
9. [9] Kim, H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:4 (1969), 422–434.
10. [10] Ralston, S., Hill, V., Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr 155:5 (2009), 728–733.
11. [11] Lotz, M.T., Moore, M.L., Peebles, R.S. Jr, Respiratory syncytial virus and reactive airway disease. Curr Top Microbiol Immunol 372 (2013), 105–118.
12. [12] Johnson, J.E., et al. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:1 (2007), 108–119.
13. [13] Welliver, T.P., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195:8 (2007), 1126–1136.
14. [14] Everard, M.L., et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71:5 (1994), 428–432.
15. [15] Smith, P.K., et al. Leucocyte populations in respiratory syncytial virus-induced bronchiolitis. J Paediatr Child Health 37:2 (2001), 146–151.
16. [16] Rosenberg, H.F., Domachowske, J.B., Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem 19:10 (2012), 1424–1431.
17. [17] Brearey, S.P., Smyth, R.L., Pathogenesis of RSV in children. Cane, P., (eds.) Respiratory syncytial virus, 2007, Elsevier, 141–162.
18. [18] Stoppelenburg, A.J., et al. Elevated Th17 response in infants undergoing respiratory viral infection. Am J Pathol 184:5 (2014), 1274–1279.
19. [19] Choi, E.H., Lee, H.J., Chanock, S.J., Human genetics and respiratory syncytial virus disease: current findings and future approaches. Curr Top Microbiol Immunol 372 (2013), 121–137.
20. [20] Hull, J., Genetic susceptibility to RSV disease. Cane, P., (eds.) Respiratory syncytial virus, 2007, Elsevier, 115–139.
21. [21] Thompson, T.M., et al. Viral specific factors contribute to clinical respiratory syncytial virus disease severity differences in infants. Clin Microbiol, 4(3), 2015.
22. [22] Morris, J.A., Blount, R.E. Jr, Savage, R.E., Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 92:3 (1956), 544–549.
23. [23] Belshe, R.B., et al. Experimental respiratory syncytial virus infection of four species of primates. J Med Virol 1:3 (1977), 157–162.
24. [24] Crowe, J.E. Jr, et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:14 (1993), 1395–1404.
25. [25] Clarke, C.J., et al. Respiratory syncytial virus-associated bronchopneumonia in a young chimpanzee. J Comp Pathol 110:2 (1994), 207–212.
26. [26] Szentiks, C.A., et al. Lethal pneumonia in a captive juvenile chimpanzee (Pan troglodytes) due to human-transmitted human respiratory syncytial virus (HRSV) and infection with Streptococcus pneumoniae. J Med Primatol 38:4 (2009), 236–240.
27. [27] Unwin, S., Chatterton, J., Chantrey, J., Management of severe respiratory tract disease caused by human respiratory syncytial virus and Streptococcus pneumoniae in captive chimpanzees (Pan troglodytes). J Zoo Wildl Med 44:1 (2013), 105–115.
28. [28] Kondgen, S., et al. Pandemic human viruses cause decline of endangered great apes. Curr Biol 18:4 (2008), 260–264.
29. [29] Nguyen, D.T., et al. Streptococcus pneumoniae enhances human respiratory syncytial virus infection in vitro and in vivo. PLoS ONE, 10(5), 2015, e0127098.
30. [30] Crowe, J.E. Jr, et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:9 (1994), 783–790.
31. [31] Collins, P.L., Murphy, B.R., New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2:2 (2005), 166–173.
32. [32] Richardson, L.S., et al. Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness. J Med Virol 3:2 (1978), 91–100.
33. [33] Crowe, J.E. Jr, et al. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:9 (1995), 847–855.
34. [34] Karron, R.A., Buchholz, U.J., Collins, P.L., Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372 (2013), 259–284.
35. [35] Collins, P.L., et al. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:2 (1990), 164–168.
36. [36] Jin, H., et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:25–26 (2003), 3647–3652.
37. [37] Le Nouen, C., et al. Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization. Proc Natl Acad Sci USA 111:36 (2014), 13169–13174.
38. [38] Jones, B.G., et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30:5 (2012), 959–968.
39. [39] Tang, R.S., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78:20 (2004), 11198–11207.
40. [40] Eyles, J.E., et al. Nonreplicating vaccines can protect African green monkeys from the Memphis 37 strain of respiratory syncytial virus. J Infect Dis 208:2 (2013), 319–329.
41. [41] Bates, J.T., et al. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine 34:7 (2016), 950–956.
42. [42] Kakuk, T.J., et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 167:3 (1993), 553–561.
43. [43] Ispas, G., et al. Antiviral activity of TMC353121, a Respiratory Syncytial Virus (RSV) fusion inhibitor, in a non-human primate model. PLoS ONE, 10(5), 2015, e0126959.
44. [44] McArthur-Vaughan, K., Gershwin, L.J., A rhesus monkey model of respiratory syncytial virus infection. J Med Primatol 31:2 (2002), 61–73.
45. [45] Vaughan, K., Rhodes, G.H., Gershwin, L.J., DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 23:22 (2005), 2928–2942.
46. [46] Babu, P.G., et al. A primate model of respiratory syncytial virus infection. Indian J Exp Biol 36:8 (1998), 758–762.
47. [47] Simoes, E.A., et al. Respiratory syncytial virus infects the Bonnet monkey, Macaca radiata. Pediatr Dev Pathol 2:4 (1999), 316–326.
48. [48] Ponnuraj, E.M., et al. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J Gen Virol 82:Pt 11 (2001), 2663–2674.
49. [49] De Swart, R.L., et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 76:22 (2002), 11561–11569.
50. [50] Weltzin, R., et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 174:2 (1996), 256–261.
51. [51] Grunwald, T., et al. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. J Virol 88:8 (2014), 3997–4007.
52. [52] Grandin, C., et al. Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques. J Gen Virol 96:Pt 4 (2015), 782–792.
53. [53] Ponnuraj, E.M., et al. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 187:8 (2003), 1257–1263.
54. [54] Prince, G.A., et al. Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants. Infect Immun 26:3 (1979), 1009–1013.
55. [55] Hemming, V.G., et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis 152:5 (1985), 1083–1087.
56. [56] Hemming, V.G., et al. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 8:1 (1995), 22–33.
57. [57] Richardson, L.S., et al. Experimental respiratory syncytial virus pneumonia in cebus monkeys. J Med Virol 2:1 (1978), 45–59.
58. [58] Papin, J.F., et al. Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infants. Am J Physiol Lung Cell Mol Physiol 304:8 (2013), L530–L539.
59. [59] Olivier, A., et al. Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. Int J Exp Pathol 90:4 (2009), 431–438.
60. [60] Derscheid, R.J., et al. Human respiratory syncytial virus Memphis 37 causes acute respiratory disease in perinatal lamb lung. Biores Open Access 3:2 (2014), 60–69.
61. [61] Larios Mora, A., et al. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) infection in the respiratory tract of newborn lambs as an RSV infection model for human infants. PLoS ONE, 10(12), 2015, e0143580.
62. [62] Sow, F.B., et al. Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. Am J Physiol Lung Cell Mol Physiol 300:1 (2011), L12–L24.
63. [63] Derscheid, R.J., et al. Effects of formalin-inactivated respiratory syncytial virus (FI-RSV) in the perinatal lamb model of RSV. PLoS ONE, 8(12), 2013, e81472.
64. [64] Garg, R., et al. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs. Vaccine 34:2 (2016), 261–269.
65. [65] Boukhvalova, M.S., Blanco, J.C., The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol 372 (2013), 347–358.
66. [66] Openshaw, P.J., The mouse model of respiratory syncytial virus disease. Curr Top Microbiol Immunol 372 (2013), 359–369.
67. [67] Byrd, L.G., Prince, G.A., Animal models of respiratory syncytial virus infection. Clin Infect Dis 25:6 (1997), 1363–1368.
68. [68] Prince, G.A., et al. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:3 (1978), 771–791.
69. [69] Stittelaar, K.J., et al. Ferrets as a novel animal model for studying human respiratory syncytial virus infections in immunocompetent and immunocompromised hosts. Viruses, 8(6), 2016.
70. [70] Lemon, K., et al. Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats. J Virol 89:5 (2015), 2849–2856.
71. [71] Boukhvalova, M.S., et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis 195:4 (2007), 511–518.
72. [72] Shaw, C.A., et al. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease. Vaccine 31:2 (2013), 306–312.
73. [73] Boukhvalova, M., et al. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant 51:1 (2016), 119–126.
74. [74] Wong, D.T., et al. Respiratory syncytial virus infection in immunosuppressed animals: implications in human infection. J Med Virol 17:4 (1985), 359–370.
75. [75] Prince, G.A., Horswood, R.L., Chanock, R.M., Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55:3 (1985), 517–520.
76. [76] The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531–7.
77. [77] Prince, G.A., et al. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82:Pt 12 (2001), 2881–2888.
78. [78] Prince, G.A., et al. Respiratory syncytial virus infection in inbred mice. Infect Immun 26:2 (1979), 764–766.
79. [79] Rameix-Welti, M.A., et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun, 5, 2014, 5104.
80. [80] Taylor, G., et al. Respiratory syncytial virus infection in mice. Infect Immun 43:2 (1984), 649–655.
81. [81] Graham, B.S., et al. Primary respiratory syncytial virus infection in mice. J Med Virol 26:2 (1988), 153–162.
82. [82] Bhoj, V.G., et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 105:37 (2008), 14046–14051.
83. [83] Jafri, H.S., et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 189:10 (2004), 1856–1865.
84. [84] Mukherjee, S., et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 179:1 (2011), 248–258.
85. [85] Graham, B.S., et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88:3 (1991), 1026–1033.
86. [86] Stokes, K.L., et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85:12 (2011), 5782–5793.
87. [87] Peebles, R.S. Jr, Graham, B.S., Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2:2 (2005), 110–115.
88. [88] Graham, B.S., et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151:4 (1993), 2032–2040.
89. [89] Knudson, C.J., et al. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog, 11(3), 2015, e1004757.
90. [90] Connors, M., et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68:8 (1994), 5321–5325.
91. [91] Connors, M., et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66:12 (1992), 7444–7451.
92. [92] Polack, F.P., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196:6 (2002), 859–865.
93. [93] Delgado, M.F., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:1 (2009), 34–41.
94. [94] Boelen, A., et al. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19 (2001), 989–991.
95. [95] Kruijsen, D., et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 29:15 (2011), 2730–2741.
96. [96] Taylor, G., et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:1 (1984), 137–142.
97. [97] Tempest, P.R., et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N Y) 9:3 (1991), 266–271.
98. [98] Mestas, J., Hughes, C., Of mice and men: differences between mouse and human immunology. J Immunol 172 (2004), 2731–2738.
99. [99] Wyatt, L., et al. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18 (2000), 392–397.
100. [100] de Waal, L., et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22:8 (2004), 923–926.
101. [101] Sharma, A., et al. Respiratory Syncytial Virus (RSV) pulmonary infection in humanized mice induces human anti-RSV immune responses and pathology. J Virol 90:10 (2016), 5068–5074.
102. [102] Harker, J.A., et al. Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol 88:1 (2014), 604–611.
103. [103] Coates, H., Chanock, R.M., Experimental infection with respiratory syncytial virus in several species of animals. Am J Epidemiol 76 (1962), 302–312.
104. [104] Prince, G.A., Porter, D.D., The pathogenesis of respiratory syncytial virus infection in infant ferrets. Am J Pathol 82:2 (1976), 339–352.
105. [105] Hegele, R.G., et al. Production of acute bronchiolitis in guinea-pigs by human respiratory syncytial virus. Eur Respir J 6:9 (1993), 1324–1331.
106. [106] Wright, P.F., Woodend, W.G., Chanock, R.M., Temperature-sensitive mutants of respiratory syncytial virus: in-vivo studies in hamsters. J Infect Dis 122:6 (1970), 501–512.
107. [107] Schmidt, A.C., et al. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75:10 (2001), 4594–4603.
108. [108] Mackow, N., et al. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) expressing the fusion glycoprotein of human Respiratory Syncytial Virus (RSV) as a bivalent HPIV1/RSV vaccine. J Virol 89:20 (2015), 10319–10332.
109. [109] Gitiban, N., et al. Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus. J Virol 79:10 (2005), 6035–6042.
110. [110] Grieves, J.L., et al. Mapping the anatomy of respiratory syncytial virus infection of the upper airways in chinchillas (Chinchilla lanigera). Comp Med 60:3 (2010), 225–232.
111. [111] Taylor, G., Bovine model of respiratory syncytial virus infection. Curr Top Microbiol Immunol 372 (2013), 327–345.
112. [112] Dyer, K.D., et al. The Pneumonia Virus of Mice (PVM) model of acute respiratory infection. Viruses 4:12 (2012), 3494–3510.
113. [113] Sacco, R.E., et al. Respiratory syncytial virus infection in cattle. Vet Pathol 51:2 (2014), 427–436.
114. [114] Kimman, T.G., Westenbrink, F., Immunity to human and bovine respiratory syncytial virus. Arch Virol 112:1–2 (1990), 1–25.
115. [115] Elvander, M., Severe respiratory disease in dairy cows caused by infection with bovine respiratory syncytial virus. Vet Rec 138:5 (1996), 101–105.
116. [116] Viuff, B., et al. Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus. Am J Pathol 161:6 (2002), 2195–2207.
117. [117] Valarcher, J.F., Taylor, G., Bovine respiratory syncytial virus infection. Vet Res 38:2 (2007), 153–180.
118. [118] Buchholz, U.J., et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol 74:3 (2000), 1187–1199.
119. [119] van der Poel, W.H., et al. Experimental reproduction of respiratory disease in calves with non-cell-culture-passaged bovine respiratory syncytial virus. Vet Q 18:3 (1996), 81–86.
120. [120] West, K., et al. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves. Vaccine 17:7–8 (1999), 809–820.
121. [121] Woolums, A.R., et al. Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus. Am J Vet Res 60:4 (1999), 473–480.
122. [122] Blodorn, K., et al. A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. BMC Vet Res, 11, 2015, 76.
123. [123] Rontved, C.M., et al. Increased pulmonary secretion of tumor necrosis factor-alpha in calves experimentally infected with bovine respiratory syncytial virus. Vet Immunol Immunopathol 76:3–4 (2000), 199–214.
124. [124] Antonis, A.F., et al. Age-dependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence. J Gen Virol 91:Pt 10 (2010), 2497–2506.
125. [125] Taylor, G., Thomas, L.H., Stott, E.J., Effect of vaccination on cell populations in lung washes from calves after infection with respiratory syncytial virus. Res Vet Sci 47:2 (1989), 231–235.
126. [126] Taylor, G., et al. Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. J Virol 69:11 (1995), 6658–6664.
127. [127] Thomas, L.H., et al. Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syncytial virus. J Infect Dis 177:4 (1998), 874–880.
128. [128] Taylor, G., et al. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 73:Pt 9 (1992), 2217–2223.
129. [129] Schreiber, P., et al. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. J Vet Med B Infect Dis Vet Public Health 47:7 (2000), 535–550.
130. [130] Kimman, T.G., et al. A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine. Vet Q 11:4 (1989), 250–253.
131. [131] Antonis, A.F., et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol 77:22 (2003), 12067–12073.
132. [132] Gershwin, L.J., et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16:11–12 (1998), 1225–1236.
133. [133] Kalina, W.V., et al. Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. Vaccine 22:11–12 (2004), 1465–1474.
134. [134] Schmidt, U., et al. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. J Virol 76:23 (2002), 12355–12359.
135. [135] Valarcher, J.F., et al. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 77:15 (2003), 8426–8439.
136. [136] Taylor, G., et al. Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. J Gen Virol 95:Pt 6 (2014), 1244–1254.
137. [137] Taylor, G., et al. DNA vaccination against respiratory syncytial virus in young calves. Vaccine 23:10 (2005), 1242–1250.
138. [138] Riffault, S., et al. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28:21 (2010), 3722–3734.
139. [139] Hagglund, S., et al. Bovine respiratory syncytial virus ISCOMs-immunity, protection and safety in young conventional calves. Vaccine 29:47 (2011), 8719–8730.
140. [140] Vangeel, I., et al. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV. Vet J 174:3 (2007), 627–635.
141. [141] Antonis, A.F., et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25:25 (2007), 4818–4827.
142. [142] Taylor, G., et al. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J Gen Virol 78:Pt 12 (1997), 3195–3206.
143. [143] Mapletoft, J.W., et al. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353:2 (2006), 316–323.
144. [144] Ellis, J.A., Gow, S.P., Goji, N., Response to experimentally induced infection with bovine respiratory syncytial virus following intranasal vaccination of seropositive and seronegative calves. J Am Vet Med Assoc 236:9 (2010), 991–999.
145. [145] Taylor, G., et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med, 7(300), 2015, 300ra127.
146. [146] Green, C.A., et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med, 7(300), 2015, 300ra126.
147. [147] Horsfall, F.L., Hahn, R.G., A latent virus in normal mice capable of producing pneumonia in its natural host. J Exp Med 71:3 (1940), 391–408.
148. [148] Anh, D.B., Faisca, P., Desmecht, D.J., Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains. Am J Physiol Lung Cell Mol Physiol 291:3 (2006), L426–L435.
149. [149] Bonville, C.A., et al. Diminished inflammatory responses to natural pneumovirus infection among older mice. Virology 368:1 (2007), 182–190.
150. [150] Bonville, C.A., et al. Inflammatory responses to acute pneumovirus infection in neonatal mice. Virol J, 7, 2010, 320.
151. [151] Krempl, C.D., Collins, P.L., Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of mice. J Virol 78:23 (2004), 13362–13365.
152. [152] Cook, P.M., Eglin, R.P., Easton, A.J., Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization. J Gen Virol 79:Pt 10 (1998), 2411–2417.
153. [153] Watkiss, E.R., et al. Innate and adaptive immune response to pneumonia virus of mice in a resistant and a susceptible mouse strain. Viruses 5:1 (2013), 295–320.
154. [154] Domachowske, J.B., et al. Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. Cell Immunol 200:2 (2000), 98–104.
155. [155] Bonville, C.A., et al. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology 349:1 (2006), 87–95.
156. [156] Domachowske, J.B., et al. The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol 165:5 (2000), 2677–2682.
157. [157] Domachowske, J.B., et al. MIP-1alpha is produced but it does not control pulmonary inflammation in response to respiratory syncytial virus infection in mice. Cell Immunol 206:1 (2000), 1–6.
158. [158] Walsh, K.B., et al. Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol 88:11 (2014), 6281–6293.
159. [159] Percopo, C.M., et al. Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice. J Immunol 183:1 (2009), 604–612.
160. [160] Maunder, H.E., et al. Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice. Vaccine 33:48 (2015), 6641–6649.